None listed
Conditions
Brief summary
Cophenylcaine (a combination of lignocaine and phenylephrine, a local anaesthetic and decongestant respectively) is commonly used as a spray to make the inside of the nose numb in Otolaryngology (ear, nose and throat surgery) clinics. However, other local anaesthetics like tetracaine are more potent than lignocaine, and phenylephrine tastes very bitter whereas other decongestants like oxymetazoline are essentially tasteless. Our hypothesis is that a tetracaine/oxymetazoline spray will act more quickly and give better anaesthesia to the inside of the nose than cophenylcaine. We will test cophenylcaine and three different concentrations of tetracaine/oxymetazoline in ten healthy participants. We will give them two sprays of one anaesthetic/decongestant in one nostril, and two sprays of another anaesthetic/decongestant in the other nostril, and measure the sensation of the lining of the nose at regular intervals using fine hair-like filaments designed for this purpose. Then, we will do the same thing with the other two anaesthetic/decongestants at least one day later, so that all participants will receive all four anaesthetic/decongestants. This will show clearly whether tetracaine/oxymetazoline gives better nasal anaesthesia than cophenylcaine, and if so, which concentration of tetracaine is best for this purpose.
Interventions
Tetracaine 0.5% + oxymetazoline 0.05% spray (1 mg tetracaine, 0.1 mg oxymetazoline) Tetracaine 1% + oxymetazoline 0.05% spray (2 mg tetracaine, 0.1 mg oxymetazoline) Tetracaine 2% + oxymetazoline 0.05% spray (4 mg tetracaine, 0.1 mg oxymetazoline) 0.2 mL of each preparation will be given intranasally as a spray, as a single exposure. The absolute doses of each drug for this volume of each preparation are given above. Participants will be randomised to receive one of these sprays or cophenylcaine (control) in each nasal cavity. This will be given by an investigator (either a specialist or advanced trainee in Otolaryngology Head and Neck Surgery) in two sittings at least one day apart so that each participant will receive all four sprays in a random order in a consistent, reproducible manner.
Sponsors
Study design
Eligibility
Inclusion criteria
Able and willing to provide informed consent to participate
Exclusion criteria
Unable to provide informed consent, or non-consenting Known hypersensitivity to constituents of the test solutions Pregnancy Acute unwellness Smoking Sinonasal or systemic disease affecting the sinonasal mucosa - Granulomatous disease - Vasculitis - Cystic Fibrosis - Ciliary dysmotility - Immune deficiency - Rhinosinusitis